Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.23
MCK's Cash-to-Debt is ranked lower than
68% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.69 vs. MCK: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
MCK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.46 Max: 3.01
Current: 0.23
0.05
3.01
Equity-to-Asset 0.15
MCK's Equity-to-Asset is ranked lower than
93% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.44 vs. MCK: 0.15 )
Ranked among companies with meaningful Equity-to-Asset only.
MCK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.26 Max: 0.35
Current: 0.15
0.13
0.35
Debt-to-Equity 0.97
MCK's Debt-to-Equity is ranked lower than
63% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.56 vs. MCK: 0.97 )
Ranked among companies with meaningful Debt-to-Equity only.
MCK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16  Med: 0.54 Max: 1.51
Current: 0.97
0.16
1.51
Debt-to-EBITDA 6.35
MCK's Debt-to-EBITDA is ranked higher than
66% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.37 vs. MCK: 6.35 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MCK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.04  Med: 1.73 Max: 6.35
Current: 6.35
1.04
6.35
Interest Coverage 10.57
MCK's Interest Coverage is ranked higher than
59% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.71 vs. MCK: 10.57 )
Ranked among companies with meaningful Interest Coverage only.
MCK' s Interest Coverage Range Over the Past 10 Years
Min: 8.31  Med: 9.45 Max: 11.27
Current: 10.57
8.31
11.27
Piotroski F-Score: 5
Altman Z-Score: 4.04
Beneish M-Score: -2.58
WACC vs ROIC
10.14%
30.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 1.37
MCK's Operating Margin % is ranked lower than
54% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.60 vs. MCK: 1.37 )
Ranked among companies with meaningful Operating Margin % only.
MCK' s Operating Margin % Range Over the Past 10 Years
Min: 1.12  Med: 1.82 Max: 1.91
Current: 1.37
1.12
1.91
Net Margin % 0.06
MCK's Net Margin % is ranked lower than
51% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.61 vs. MCK: 0.06 )
Ranked among companies with meaningful Net Margin % only.
MCK' s Net Margin % Range Over the Past 10 Years
Min: 0.03  Med: 1.08 Max: 2.55
Current: 0.06
0.03
2.55
ROE % 1.15
MCK's ROE % is ranked higher than
98% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.39 vs. MCK: 1.15 )
Ranked among companies with meaningful ROE % only.
MCK' s ROE % Range Over the Past 10 Years
Min: 0.64  Med: 18.14 Max: 50.65
Current: 1.15
0.64
50.65
ROA % 0.19
MCK's ROA % is ranked higher than
88% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.37 vs. MCK: 0.19 )
Ranked among companies with meaningful ROA % only.
MCK' s ROA % Range Over the Past 10 Years
Min: 0.11  Med: 4.01 Max: 8.63
Current: 0.19
0.11
8.63
ROC (Joel Greenblatt) % 16.07
MCK's ROC (Joel Greenblatt) % is ranked higher than
97% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.92 vs. MCK: 16.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MCK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.07  Med: 165.2 Max: 261.54
Current: 16.07
16.07
261.54
3-Year Revenue Growth Rate 9.40
MCK's 3-Year Revenue Growth Rate is ranked higher than
68% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.70 vs. MCK: 9.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MCK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.6  Med: 11.4 Max: 23.7
Current: 9.4
-13.6
23.7
3-Year EBITDA Growth Rate -25.80
MCK's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.60 vs. MCK: -25.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MCK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -68.1  Med: 15.4 Max: 297.2
Current: -25.8
-68.1
297.2
3-Year EPS without NRI Growth Rate -65.90
MCK's 3-Year EPS without NRI Growth Rate is ranked higher than
97% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.10 vs. MCK: -65.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MCK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.9 Max: 87.1
Current: -65.9
0
87.1
GuruFocus has detected 3 Warning Signs with McKesson Corp MCK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MCK's 30-Y Financials

Financials (Next Earnings Date: 2019-01-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

MCK Guru Trades in Q3 2017

Seth Klarman 500,000 sh (New)
George Soros 69,000 sh (New)
Larry Robbins 2,720,878 sh (+129.06%)
Tom Gayner 26,100 sh (+72.85%)
Richard Pzena 2,458,531 sh (+17.19%)
John Buckingham 22,495 sh (+6.90%)
Jerome Dodson 168,000 sh (unchged)
Vanguard Health Care Fund 8,002,819 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
David Dreman 6,834 sh (unchged)
First Pacific Advisors 26,550 sh (unchged)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 70,956 sh (-0.57%)
Manning & Napier Advisors, Inc 20,970 sh (-1.87%)
Arnold Van Den Berg 85,965 sh (-2.26%)
Joel Greenblatt 222,026 sh (-15.65%)
Charles Brandes 730,251 sh (-25.43%)
Ray Dalio 34,346 sh (-29.49%)
Jim Simons 565,200 sh (-43.53%)
Diamond Hill Capital 3,782 sh (-84.23%)
Steven Cohen 45,000 sh (-92.13%)
» More
Q4 2017

MCK Guru Trades in Q4 2017

Pioneer Investments 391,307 sh (New)
Tom Russo 95 sh (New)
Seth Klarman 1,360,000 sh (+172.00%)
Steven Cohen 63,900 sh (+42.00%)
Ray Dalio 48,153 sh (+40.20%)
Larry Robbins 3,801,966 sh (+39.73%)
Arnold Van Den Berg 97,950 sh (+13.94%)
Richard Pzena 2,600,401 sh (+5.77%)
John Buckingham 22,928 sh (+1.92%)
Mario Gabelli 5,000 sh (unchged)
Tom Gayner 26,100 sh (unchged)
David Dreman 6,834 sh (unchged)
Jerome Dodson Sold Out
Jim Simons Sold Out
Charles Brandes 730,069 sh (-0.02%)
Ronald Muhlenkamp 69,947 sh (-1.42%)
Vanguard Health Care Fund 7,432,504 sh (-7.13%)
George Soros 56,500 sh (-18.12%)
Diamond Hill Capital 1,662 sh (-56.05%)
Joel Greenblatt 81,265 sh (-63.40%)
First Pacific Advisors 3,100 sh (-88.32%)
» More
Q1 2018

MCK Guru Trades in Q1 2018

Jeremy Grantham 102,500 sh (New)
Steven Cohen 112,700 sh (+76.37%)
Pioneer Investments 553,555 sh (+41.46%)
George Soros 68,255 sh (+20.81%)
Seth Klarman 1,615,700 sh (+18.80%)
Larry Robbins 4,398,271 sh (+15.68%)
Tom Gayner 30,100 sh (+15.33%)
Ronald Muhlenkamp 71,090 sh (+1.63%)
Richard Pzena 2,635,648 sh (+1.36%)
Diamond Hill Capital 1,663 sh (+0.06%)
David Dreman 6,834 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
Tom Russo Sold Out
First Pacific Advisors Sold Out
Joel Greenblatt Sold Out
Charles Brandes 724,337 sh (-0.79%)
Vanguard Health Care Fund 7,162,604 sh (-3.63%)
John Buckingham 21,543 sh (-6.04%)
Arnold Van Den Berg 89,065 sh (-9.07%)
Ray Dalio 5,251 sh (-89.10%)
» More
Q2 2018

MCK Guru Trades in Q2 2018

John Hussman 400 sh (New)
Paul Tudor Jones 30,487 sh (New)
Joel Greenblatt 126,503 sh (New)
Ray Dalio 56,752 sh (+980.78%)
Diamond Hill Capital 2,317 sh (+39.33%)
Tom Gayner 37,100 sh (+23.26%)
Richard Pzena 2,836,710 sh (+7.63%)
Larry Robbins 4,710,544 sh (+7.10%)
John Buckingham 22,286 sh (+3.45%)
Seth Klarman 1,627,700 sh (+0.74%)
Charles Brandes 727,626 sh (+0.45%)
Mario Gabelli 5,000 sh (unchged)
Ronald Muhlenkamp 71,090 sh (unchged)
Zeke Ashton 21,000 sh (unchged)
George Soros Sold Out
Steven Cohen Sold Out
Arnold Van Den Berg 88,299 sh (-0.86%)
Vanguard Health Care Fund 6,985,304 sh (-2.48%)
Jeremy Grantham 95,378 sh (-6.95%)
Pioneer Investments 137,291 sh (-75.20%)
» More
» Details

Insider Trades

Latest Guru Trades with MCK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 424210    SIC: 5122
Compare:NYSE:CAH, NYSE:ABC, XKRX:091990, NAS:HSIC, HKSE:01099, SHSE:601607, TSE:7459, SZSE:002589, SHSE:600056, SZSE:200028, LSE:UDG, SHSE:600763, NAS:PDCO, NZSE:EBO, SHSE:600090, NYSE:PBH, LSE:CLIN, SHSE:603368, TSE:7476, NYSE:OMI » details
Traded in other countries:MCK.Germany, MCK.Mexico,
Headquarter Location:USA
McKesson Corp provides medicines, pharmaceutical supplies, information and care management products and services across the healthcare industry. It operates with two segments namely McKesson Distribution Solutions and McKesson Technology Solutions.

McKesson is one of three major distributors of pharmaceuticals in the U.S. The firm also has significant specialty drug and medical product wholesaling operations. The firm plays a critical role along the pharmaceutical supply chain as it is able to procure and distribute drugs more efficiently than its pharmacy client and pharma manufacturing suppliers.

Guru Investment Theses on McKesson Corp

Weitz Funds Comments on McKesson - Jan 26, 2017

McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Top Ranked Articles about McKesson Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of McKesson Corporation - MCK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of McKesson Corporation - MCK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of McKesson Corporation - MCK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claim On Behalf of Investors of McKesson Corporation - MCK
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against McKesson Corporation (MCK) and Lead Plaintiff Deadline: December 26, 2018
Shareholder Alert - Bleichmar Fonti & Auld LLP Files Securities Class Action Lawsuit Against McKesson Corporation
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of McKesson Corporation (MCK)
2 Seth Klarman Stocks Fall to 52-Week Lows Master of value investing has two stocks in his portfolio that investors can purchase at relatively low prices
Seth Klarman (Trades, Portfolio), considered a master of value investing, has two stocks in his portfolio that investors can purchase at relatively low prices. Read more...
McKesson Corporation Announces Offer to Purchase Up to $1,100,000,000 Combined Purchase Price of Outstanding 6.000% Notes due 2041, 7.650% Debentures due 2027, 4.883% Notes due 2044, 4.750% Notes due 2021 and 7.500% Notes due 2019
Value Screeners Identify Good Opportunities for 2018 A look at the value screener record and model portfolios
GuruFocus offers several value-investing strategies that have outperformed the S&P 500 benchmark throughout the past eight years. Three such strategies include the Undervalued Predictable Strategy, the Buffett-Munger Strategy and the Most Broadly Held Strategy. Read more...

Ratios

vs
industry
vs
history
PE Ratio 182.19
MCK's PE Ratio is ranked higher than
94% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.00 vs. MCK: 182.19 )
Ranked among companies with meaningful PE Ratio only.
MCK' s PE Ratio Range Over the Past 10 Years
Min: 5.98  Med: 17.26 Max: 510.1
Current: 182.19
5.98
510.1
Forward PE Ratio 9.25
MCK's Forward PE Ratio is ranked higher than
77% of the 13 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.99 vs. MCK: 9.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 187.71
MCK's PE Ratio without NRI is ranked higher than
94% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.94 vs. MCK: 187.71 )
Ranked among companies with meaningful PE Ratio without NRI only.
MCK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.83  Med: 17.17 Max: 545.28
Current: 187.71
5.83
545.28
Price-to-Owner-Earnings 64.66
MCK's Price-to-Owner-Earnings is ranked higher than
94% of the 35 Companies
in the Global Medical Distribution industry.

( Industry Median: 18.94 vs. MCK: 64.66 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MCK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.59  Med: 12.52 Max: 70.43
Current: 64.66
3.59
70.43
PB Ratio 2.60
MCK's PB Ratio is ranked lower than
60% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.12 vs. MCK: 2.60 )
Ranked among companies with meaningful PB Ratio only.
MCK' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.94 Max: 6.98
Current: 2.6
1.31
6.98
PS Ratio 0.12
MCK's PS Ratio is ranked higher than
88% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.91 vs. MCK: 0.12 )
Ranked among companies with meaningful PS Ratio only.
MCK' s PS Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.18 Max: 0.32
Current: 0.12
0.08
0.32
Price-to-Free-Cash-Flow 9.20
MCK's Price-to-Free-Cash-Flow is ranked lower than
52% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.20 vs. MCK: 9.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MCK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 12.27 Max: 41.89
Current: 9.2
5.4
41.89
Price-to-Operating-Cash-Flow 7.61
MCK's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 31 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.02 vs. MCK: 7.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MCK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 10.24 Max: 89.13
Current: 7.61
4.87
89.13
EV-to-EBIT 66.92
MCK's EV-to-EBIT is ranked higher than
94% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.52 vs. MCK: 66.92 )
Ranked among companies with meaningful EV-to-EBIT only.
MCK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 11.4 Max: 604.7
Current: 66.92
4.9
604.7
EV-to-EBITDA 21.92
MCK's EV-to-EBITDA is ranked higher than
96% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.88 vs. MCK: 21.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
MCK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 9.1 Max: 37.3
Current: 21.92
4.3
37.3
EV-to-Revenue 0.15
MCK's EV-to-Revenue is ranked higher than
93% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.93 vs. MCK: 0.15 )
Ranked among companies with meaningful EV-to-Revenue only.
MCK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 0.2 Max: 0.4
Current: 0.15
0.1
0.4
PEG Ratio 117.31
MCK's PEG Ratio is ranked higher than
89% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.54 vs. MCK: 117.31 )
Ranked among companies with meaningful PEG Ratio only.
MCK' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 1.1 Max: 117.31
Current: 117.31
0.11
117.31
Shiller PE Ratio 17.01
MCK's Shiller PE Ratio is ranked higher than
67% of the 21 Companies
in the Global Medical Distribution industry.

( Industry Median: 27.63 vs. MCK: 17.01 )
Ranked among companies with meaningful Shiller PE Ratio only.
MCK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.91  Med: 28.05 Max: 51.86
Current: 17.01
14.91
51.86
Current Ratio 0.99
MCK's Current Ratio is ranked lower than
91% of the 54 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.50 vs. MCK: 0.99 )
Ranked among companies with meaningful Current Ratio only.
MCK' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.25 Max: 1.71
Current: 0.99
0.99
1.71
Quick Ratio 0.56
MCK's Quick Ratio is ranked lower than
91% of the 54 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.12 vs. MCK: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
MCK' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 0.65 Max: 0.94
Current: 0.56
0.52
0.94
Days Inventory 30.48
MCK's Days Inventory is ranked higher than
67% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 41.27 vs. MCK: 30.48 )
Ranked among companies with meaningful Days Inventory only.
MCK' s Days Inventory Range Over the Past 10 Years
Min: 29.24  Med: 30.99 Max: 32.98
Current: 30.48
29.24
32.98
Days Sales Outstanding 33.25
MCK's Days Sales Outstanding is ranked higher than
82% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 60.84 vs. MCK: 33.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
MCK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.36  Med: 31.03 Max: 36.61
Current: 33.25
24.36
36.61
Days Payable 60.77
MCK's Days Payable is ranked lower than
52% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 62.55 vs. MCK: 60.77 )
Ranked among companies with meaningful Days Payable only.
MCK' s Days Payable Range Over the Past 10 Years
Min: 50.74  Med: 58.14 Max: 60.77
Current: 60.77
50.74
60.77

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.14
MCK's Dividend Yield % is ranked lower than
75% of the 68 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.59 vs. MCK: 1.14 )
Ranked among companies with meaningful Dividend Yield % only.
MCK' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.77 Max: 1.42
Current: 1.14
0.35
1.42
Dividend Payout Ratio 2.24
MCK's Dividend Payout Ratio is ranked higher than
96% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.28 vs. MCK: 2.24 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MCK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.14 Max: 4.33
Current: 2.24
0.05
4.33
3-Year Dividend Growth Rate 10.60
MCK's 3-Year Dividend Growth Rate is ranked lower than
64% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.70 vs. MCK: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MCK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -21.7  Med: 0 Max: 44.2
Current: 10.6
-21.7
44.2
Forward Dividend Yield % 1.26
MCK's Forward Dividend Yield % is ranked lower than
77% of the 69 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.45 vs. MCK: 1.26 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.76
MCK's 5-Year Yield-on-Cost % is ranked lower than
83% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.97 vs. MCK: 1.76 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MCK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.55  Med: 1.21 Max: 2.23
Current: 1.76
0.55
2.23
3-Year Average Share Buyback Ratio 4.50
MCK's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.90 vs. MCK: 4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MCK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -46.3  Med: 0.3 Max: 5.7
Current: 4.5
-46.3
5.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.54
MCK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 26 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.53 vs. MCK: 0.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MCK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 0.98 Max: 30.68
Current: 0.54
0.54
30.68
Price-to-Intrinsic-Value-DCF (Earnings Based) 17.55
MCK's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
92% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.99 vs. MCK: 17.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MCK' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.26  Med: 1.66 Max: 45.44
Current: 17.55
0.26
45.44
Price-to-Median-PS-Value 0.66
MCK's Price-to-Median-PS-Value is ranked higher than
60% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.96 vs. MCK: 0.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MCK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1 Max: 1.92
Current: 0.66
0.51
1.92
Earnings Yield (Greenblatt) % 1.49
MCK's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.16 vs. MCK: 1.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MCK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 8.8 Max: 20.6
Current: 1.49
0.2
20.6
Forward Rate of Return (Yacktman) % 9.47
MCK's Forward Rate of Return (Yacktman) % is ranked higher than
97% of the 34 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.37 vs. MCK: 9.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MCK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -23.5  Med: 21.8 Max: 30
Current: 9.47
-23.5
30

More Statistics

Revenue (TTM) (Mil) $210,927.00
EPS (TTM) $ 0.68
Beta1.55
Volatility26.31%
52-Week Range $117.19 - 178.86
Shares Outstanding (Mil)195.38

Analyst Estimate

Mar19 Mar20 Mar21
Revenue (Mil $) 215,198 222,891 228,561
EBIT (Mil $) 3,248 3,576 4,070
EBITDA (Mil $) 4,109 4,289 4,546
EPS ($) 11.70 12.54 14.75
EPS without NRI ($) 11.70 12.54 14.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.94%
Dividends per Share ($) 1.29 1.34 1.53

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}